
Prelude Therapeutics Incorporated PRLD
$ 2.99
-6.27%
Annual report 2025
added 03-10-2026
Country |
|
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
77 M |
Market Cap[1] |
$ 230 M |
EBITDA (LTM) |
$ -126 M |
P/E (LTM) |
-1.97 |
P/S (LTM) |
24.22 |
EPS (LTM) |
-1.52 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Benitec Biopharma
BNTC
|
$ 10.98 | -4.52 % | $ 452 M | Nasdaq Capital Market | ||
|
Ascendis Pharma A/S
ASND
|
$ 221.88 | -0.87 % | $ 5 B | Nasdaq Global Select Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Milestone Pharmaceuticals
MIST
|
$ 1.36 | -20.0 % | $ 45.5 M | Nasdaq Global Select Market | ||
|
Pharming Group N.V.
PHAR
|
$ 15.36 | -0.71 % | $ 7.59 B | Nasdaq Global Select Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Inventiva S.A.
IVA
|
$ 5.78 | -4.3 % | $ 138 M | Nasdaq Global Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Tiziana Life Sciences PLC
TLSA
|
$ 1.21 | -3.97 % | $ 71.5 M | Nasdaq Global Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
PainReform Ltd.
PRFX
|
$ 2.28 | -0.44 % | $ 1.03 M | Nasdaq Capital Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Assembly Biosciences
ASMB
|
$ 28.46 | 3.45 % | $ 319 M | Nasdaq Global Select Market,SPB | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.37 | -4.2 % | $ 350 M | Nasdaq Global Select Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Axsome Therapeutics
AXSM
|
$ 156.92 | -1.23 % | $ 7.81 B | Nasdaq Global Market,SPB | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
AbCellera Biologics
ABCL
|
$ 3.4 | -3.68 % | $ 1.02 B | Nasdaq Global Select Market | ||
|
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 54.13 | -1.64 % | $ 10.4 B | Nasdaq Global Select Market,SPB | ||
|
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | ||
|
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | ||
|
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | ||
|
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | ||
|
Compugen Ltd.
CGEN
|
$ 2.09 | -0.95 % | $ 195 M | Nasdaq Global Market,SPB | ||
|
Coherus BioSciences
CHRS
|
$ 1.52 | -5.59 % | $ 178 M | Nasdaq Global Market | ||
|
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | ||
|
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Burford Capital Limited
BUR
|
$ 7.7 | -5.87 % | $ 1.29 B | NYSE | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 8.6 | -3.8 % | $ 115 M | Nasdaq Global Market | ||
|
Curis
CRIS
|
$ 0.77 | 1.89 % | $ 4.86 M | Nasdaq Global Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.